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Abstract
Hepatitis C virus (HCV) infection is one of the major reasons for causing chronic hepatic 
disease worldwide. Treatment options for patients infected with chronic hepatitis C 
(CHC) have effectually ameliorated over the last few years. Now, various novel antiviral 
drugs have been licensed for its treatment. Introduction of direct-acting antivirals (DAAs) 
for HCV therapy represents a major advancement with regard to sustained virologic 
response (SVR) rates and associated adverse effect (AEs) profiling. Systematically, DAAs 
specifically impede different nonstructural proteins of HCV including NS3/4A prote-
ase, NS5A protein, and NS5B polymerase. In spite of those DAAs, therapy is confront-
ing multiple challenges such as possible drug-drug interactions and severe side effects 
including liver failure. This chapter discusses the safety and tolerability of DAAs rel-
evant to associated side effects emphasizing their clinical pharmacology. Considering the 
increased HCV prevalence rate and interpreting safety data of DAA regimens approved 
in the USA, Europe, Russia, Australia, and Japan, this chapter also presents the pre- and 
post-marketing safety data. Eventually, the important safety issues of drug–drug interac-
tions (DDIs) have also been discussed in brief.
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1. Introduction
Hepatitis C virus (HCV) infection, one of the major elements of liver disease worldwide [1], 
can cause both acute and chronic infections. Acute infection may follow an asymptomatic con-
dition as well as self-limited hepatitis. Almost 15–45% of HCV-infected patients impulsively 
clear out the virus within 24 weeks of infection without getting any treatment. The remaining 
55–85% of patients develop chronic infection; out of them 15–30% come across the risk of liver 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
cirrhosis within 20 years [2, 3]. Hepatitis C infection may cause liver histological changes, per-
vasive fibrosis, and cirrhosis with or without hepatic carcinoma. Furthermore, HCV infection 
may be associated with higher risk of cardiovascular disease [4, 5]. Advanced liver disease 
may lead to liver transplantation worldwide predisposing patients to a wide variety of clini-
cal manifestations, thus progressing to liver-related mortality in due sequel [6]. Viral genome 
sequences are highly variable. About 11 different genotypes have been discovered so far hav-
ing 30–50% nucleotide sequence variation; however, six genotypes are more prevalent in dif-
ferent regions. HCV genotype 1 is the most common among them representing 46.2% of all 
HCV cases followed by genotype 3 (30.1% of all HCV cases). The rest of the genotypes includ-
ing genotype 2 (9.1% of all HCV cases), genotype 4 (8.3% of all HCV cases), genotype 5 (5.4% 
of all HCV cases), and genotype 6 (<1% of all HCV cases) are less commonly found globally. 
All these genotypes also vary for their pathogenicity, virulence, and progression rate to severe 
clinical manifestations [7]. For example, HCV infection with genotype 1b is related to more 
aggressive course of hepatic disease while comparing with other genotypes [8]. Liver cirrhotic 
patients and those having decompensated liver disease requiring liver transplantation have 
more commonly found genotype 1b infection than patients exhibiting chronically active HCV 
[9]. However, rapid fibrosis progression is associated with HCV genotype 3 [10]. Furthermore, 
each genotype responds differently to pharmacological treatment. Higher resistance to inter-
feron therapy was shown in patients having genotypes 1 and 4 than with genotypes 2 and 3 [7].
Chronic HCV treatment is undergoing a continuous dynamic change. Since 1991 interferon-
based therapy for chronic hepatitis C (CHC) patients was used as the standard of care (SOC), 
but therapy had unresponsive cure rate of no more than 6% along with serious side effects 
that led to the discontinuation of treatment subsequently [11]. In the start of millennium, 
pegylated interferon (pegIFN) with guanosine analogue, ribavirin (RBV), replaced the stan-
dard interferon as a safer and well-tolerated therapy regardless of HCV genotypes [12, 13]. 
Therapeutic progress was limited due to substantial adverse event (AE) profile and minimal 
response rates particularly in HCV genotype 1-infected patients [14]. Side effects include bone 
marrow depression with lower content of granulocytes, neutropenia, and flu-like symptoms. 
Neuropsychiatric side effects such as irritability, severe fatigue, and apathy are extensive 
problems for patients and their families if not treated properly on time [15]. Furthermore, 
autoimmune diseases like rheumatoid arthritis, psoriasis, vitiligo, lichen planus, dermatitis 
herpetiformis, type 1 diabetes mellitus, and sarcoidosis can be enrooted or intensified during 
pegIFN therapy [15]. Therefore, therapy is advised with vigilance to patients having auto-
immune disease. Thyroid dysfunction and RBV-associated side effects are also linked with 
pegIFN therapy. The abovementioned side effects, prolonged duration, high cost, and lesser 
adherence to therapy lead to the discontinuation of treatment.
A new era of HCV therapy was heralded with the emergence and approval of oral direct acting 
antiviral (DAA) agents. In comparison to nonspecificity of IFN-based therapy, DAAs directly 
intend to block various proteins involved in HCV replication pathways. Recently, available DAAs 
inhibit nonstructural proteins including NS3/4A protease, NS5A protein, and NS5B polymerase 
alone or in combination with other antiviral agents involved in blocking different stages of HCV 
replication [16]. Four main classes of DAAs used in multiple combinations for HCV treatment are 
described in Table 1 [17]. First-generation protease inhibitors, telaprevir® and boceprevir®, were 
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Classes of DAAs Target proteins/enzymes Dose/combination 
used/year of approval
Targeted 
genotypes
With or without 
cirrhosis
Cure rate/course of treatment Cost of 
therapy ($)
NS3/NS4A 
protease inhibitors
NS3/NS4A inhibitors act to block 
viral protease that help virus in 
posttranslational processing and 
HCV replication
1. Glecaprevir (in 
combination with 
pibrentasvir) (2016)
2. Simeprevir (2014)
1. All six 
major 
genotypes
2. Genotypes 
1a/b
1. Without cirrhosis
2. Without cirrhosis
1. 90–100%/8–12 weeks
2. 80–90%/12 weeks
$26,400/
treatment 
course
$66,360/
treatment 
course
Nucleoside and 
nucleotide NS5B 
polymerase 
inhibitors
These inhibitors directly act 
to block viral replication 
by attaching to viral RNA 
polymerase enzyme
1. Epclusa (sofosbuvir 
and velpatasvir) 
(2016)
2. Sofosbuvir (2014)
1. All six 
major 
genotypes
2.Genotypes 
1–4
1. Both
2. Without cirrhosis
1. 100% (some groups); 
94% for decompensated 
cirrhosis/12 weeks
2. 30 –97%/12–24 weeks
$74,760
$84,000 in the 
USA
NS5A inhibitors Block directly NS5A protein 
which is required for HCV 
reproduction
1. Zepatier (elbasvir/
grazoprevir) (2016)
2. Daclatasvir (2015)
3. Ombitasvir with 
paritaprevir and 
ritonavir (2015)
4. Ledipasvir with 
sofosbuvir (2014)
1. Genotypes 1 
and 4
2. Genotype 3
3. Genotypes 1 
and 4
4. Genotype 1
1. Both
2. Both
3. Without cirrhosis
4. Both
1. 94–97% (genotype 
1); 97–100% (genotype 
4)/12–16 weeks
2. 98% (treatment-naïve) 
and 58% (treatment 
experienced patients with 
cirrhosis)/12 weeks
3. 100% 
(treatment-naïve)/12 weeks
4. 93–99%/12–24 weeks
$54,600 for 
12 weeks
$63,000 in the 
USA
$76,653
$94,500; 
12 weeks
Non-nucleoside 
NS5B polymerase 
inhibitors
They work to block HCV from 
reproduction by inserting 
themselves into virus so that other 
viral pieces cannot attach to it
1. Dasabuvir (in 
combination with 
paritaprevir and 
ombitasvir) (2014)
1. Genotype 
1a/1b
1. Both, for 
compensated 
cirrhosis (used 
with RBV)
1. >90%/12–24 weeks $83,319 in 
the USA for 
12 weeks
Table 1. List of direct acting antivirals (DAAs).
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approved in 2011 by the European Medical Academy (EMA) and Food and Drug Administration 
(FDA) for the treatment of CHC patients of genotype 1, but due to severe cutaneous AEs includ-
ing diffuse rash or localized rash with pruritus and skin peeling, therapy was discontinued in 
2012 [18, 19]. In 2014, the EMA approved four new polymerase/protease inhibitors (simepre-
vir®, sofosbuvir®, ledipasvir®, and daclatasvir®) having variable pharmacodynamic charac-
teristics such as simeprevir® which inhibits NS3/4A protease, sofosbuvir® which blocks NS5B 
polymerase, and ledipasvir® and daclatasvir® which are HCV NS5A inhibitors. The Japanese 
Ministry of Health, Labor and Welfare approved an NS3/4A protease inhibitor, asunaprevir®, 
in 2014 for the treatment of genotypes 1 and 4. Combination of asunaprevir® with daclatasvir® 
is the first oral interferon and RBV-free treatment for CHC patients having genotype 1 infection. 
This combinatorial treatment is also approved in Australia and Russia. In the following year, 
the EMA and FDA approved a new combination of drugs ombitasvir®/paritaprevir®/ritona-
vir®. Among these, ritonavir® is not active against HCV infection; rather, it is a cytochrome P450 
3A (CYP3A) inhibitor which increases systemic exposure of paritaprevir® (a CYP3A substrate). 
Ombitasvir® is an HCV NS5A inhibitor. In the same year, dasabuvir®, NS5B polymerase inhibi-
tor, was also approved by the EMA. Combination of all these drugs with or without RBV can be 
used for the treatment of HCV genotypes 1a, 1b, and 4 [20]. In January 2016, the FDA approved 
zepatier® (grazoprevir®/elbasvir®) for marketing. In May 2016, the EMA also recommended the 
granting of marketing authorizations in the EU for zepatier® treatment [20]. In the same year, 
epclusa® (combination of sofosbuvir® and velpatasvir®) was approved for the treatment of all 
six major genotypes. Recently, in July 2017, Vosevi® (combination of sofosbuvir®/velpatasvir®/
voxilaprevir®) was approved by the FDA in which each drug acts through a different mecha-
nism [21]. Vosevi® includes combination of NS5B polymerase, NS3/NS4A, and NS5A inhibitors.
2. General safety and tolerability aspects of DAAs
The basic purposes of HCV pharmacological therapy are to eliminate viral infection and to 
prevent it from causing cirrhosis and associated complications. Alleviative effects of viral phar-
macological therapies are estimated through the sustained virological response (SVR) which 
is defined as a viremia (undetectable HCV RNA in blood) 12 or 24 weeks after completion of 
anti-HCV therapy. In clinical trials, SVR is commonly used as primary efficacy end point and 
serves as the only factor linked with liver-associated events and all-cause mortality [22, 23].
2.1. Clinical efficacy and tolerability profile related to DAAs from premarketing 
studies
Fundamental characteristics of premarketing studies have been enlisted in Table 2. Antiviral 
drug’s efficacy and tolerability profile of different DAA combinations are discussed below.
2.1.1. Clinical tolerability analysis of sofosbuvir® treatment in different combinations
Clinical efficacy results of sofosbuvir pivotal studies including NEUTRINO, FISSION, POSIT-
RON, and FUSION trials depicted that the most usual AEs were nausea, headache, fatigue, 
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and insomnia. In these trials more than 1000 patients of all six major HCV genotypes were treated 
with sofosbuvir® and RBV or PegIFN and RBV. Mostly, severe AEs were observed in patients 
treated with PegIFN and RBV as compared to sofosbuvir® [24, 25]. According to safety results 
of NEUTRINO and FISSION trials, fever, depression, and influenza-like symptoms were more 
common in PegIFN-treated patients as compared to those who received sofosbuvir®. Lastly, 
POSITRON safety data illustrated that gastrointestinal disorder, administration site reactions, 
Treatment/study group/
year
Population Adverse event (AE) profile Overall 
SVR
12
 rate
Treatment status
SOF/RBV (n = 256) vs. 
PegIFNα-2a/RBV (n = 243) 
(2013) [23]
499 genotypes 2/3 
HCV patients
More patients treated with 
PegIFNα-2a/RBV had AEs. 
Common AEs in patients treated 
with SOF/RBV and PegIFNα-2a/
RBV were fatigue (36 vs. 55%), 
headache (25 vs. 44%), nausea (18 
vs. 29%), insomnia (12 vs. 29%), 
anemia (8 vs. 12%), influenza-like 
symptoms (3 vs. 16%), fever (3 
vs.18%), and depression (5 vs. 
14%)
67% 26 patients treated 
with PegIFNα-2a/
RBV and three 
patients treated 
with SOF/RBV 
discontinued their 
treatment
SOF/RBV/PegIFNα-2a 
(2013) [23]
327 genotypes 
1, 4, 5, or 6 HCV 
patients
The most common AEs included 
fatigue (59%), headache (36%), 
nausea (34%), insomnia (25%), 
and anemia (21%)
90% 8 patients
SOF/RBV (n = 207) vs. 
placebo/RBV (n = 71) 
(2013) [24]
278 genotype 2 or 3 
HCV patients
The most common AEs by SOC 
in SOF/RBV and RBV/placebo 
groups were general disorders 
and administration site reactions 
(57 vs. 36.6%), gastrointestinal 
disorders (43.5 vs. 39.4%), 
nervous system disorders (35.3 
vs. 29.6%), musculoskeletal 
and connective disorders (18.8 
vs. 7%), blood and lymphatic 
system disorders (14%vs.1.4%), 
complications (9.2 vs. 5.6%),and 
metabolism and nutrition 
disorders (7.2 vs. 12.7%)
78% 4 patients who 
received SOF/RBV 
and three patients 
who received 
placebo (4%)
SOF/RBV for 12 weeks 
(n = 103) vs. SOF/RBV for 
16 weeks (n = 98) (2013) 
[24]
201 genotype 2 or 3 
HCV patients
The most common AEs by SOC in 
SOF/RBV 12 weeks and SOF/RBV 
16 weeks groups were general 
disorders and administration 
site reactions (58.3 vs. 60.2%), 
gastrointestinal disorders 
(47.6 vs. 46.9%), infections and 
infestations (31.1 vs. 23.5%), 
nervous system disorders (36.9 
vs. 42.9%), musculoskeletal and 
connective disorders (28.2 vs. 
34.7%), psychiatric disorders 
(34 vs. 41.8%), and skin and 
subcutaneous tissue disorders (33 
vs. 31.6%)
50% 1 patient in SOF/
RBV 12 weeks 
group
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Treatment/study group/
year
Population Adverse event (AE) profile Overall 
SVR
12
 rate
Treatment status
DCV + SOF ± RBV for 
12 weeks (n = 103) vs. 
24 weeks (n = 302) (2017) 
[25]
617 HIV-/HCV-
coinfected patients 
with genotype 1, 3, 
and 4
Common AEs associated 
with DCV + SOF ± RBV were 
decompensated cirrhosis/multi-
organ failure, respiratory disorder, 
hepatic carcinoma, lymphopenia, 
and renal insufficiency
Overall 
92%
7 patients 
discontinued
LDV/SOF for 12 weeks 
(n = 109) vs. LDV/SOF/
RBV for 12 weeks (n = 111) 
vs. LDV/SOF for 24 weeks 
(n = 109) vs. LDV/SOF/
RBV for 24 weeks (n = 111) 
(2014) [26]
440 genotype 1 
HCV patients (20% 
with cirrhosis)
Six percent of patients in LDV/
SOF for 24 weeks and 3% LDV/
SOF/RBV for 24 weeks had a 
serious of AEs (P = 0.36)
More patients in RBV groups 
had fatigue, nausea, insomnia, 
arthralgia, cough, rash, 
irritability, dyspnea, and anemia.
Grade 1 or 2 hyperbilirubinemia 
occurred in more patients who 
received LDV/SOF/RBV for 
12 and 24 weeks compared to 
patients who received LDV/SOF 
for 12 and 24 weeks (32 and 41% 
vs. 1 and 7%, respectively)
>90% No AEs leading 
to treatment 
discontinuation
LDV/SOF for 8 weeks 
(n = 215) vs. LDV/SOF/
RBV for 8 weeks (n = 216) 
vs. LDV/SOF for 12 weeks 
(n = 216) (2014) [27]
647 previously 
untreated 
patients with 
HCV genotype 1 
infection
The most common AEs in LDV/
SOF for 8 weeks, LDV/SOF/RBV 
for 8 weeks, and LDV/SOF for 
12 weeks groups were fatigue 
(21 vs. 35 vs. 23%), headache (14 
vs. 25 vs. 15%), nausea (7 vs. 18 
vs. 11%), and insomnia (5 vs. 12 
vs. 7%)
Fatigue, headache, nausea, 
insomnia, irritability, rash, 
pruritus, cough, and anemia were 
more common in patients treated 
with RBV Three patients in the 
group LDV/SOF/RBV for 8 weeks 
had grade 3 hyperbilirubinemia
93–95% 1 patient in LDV/
SOF/RBV for 
8 weeks and two 
patients in LDV/
SOF for 12 weeks
DCV/SOF for 23 weeks 
(groups A and B; n = 31) 
vs. DCV/SOF for 24 weeks 
(groups C and D; n = 28) vs. 
DCV/SOF/RBV for 24 weeks 
(groups E and F; n = 29)
DCV/SOF, with or without 
RBV, for 12 weeks (group 
G; n = 41 or group H; 
n = 41) or 24 weeks (41 
patients who did not 
have a response to prior 
treatment with HCV 
protease inhibitors, (n = 21) 
or J (n = 20) (2014) [28]
211 genotypes 1–3 
HCV patients
Common AEs occurred in groups 
A and B; C and D; E and F; and 
G, H, I, and J were fatigue (29 vs. 
50 vs. 31 vs. 39 vs. 37 vs. 29 vs. 
45%), headache (16 vs. 29 vs. 38 
vs. 34 vs. 22 vs. 33 vs. 35%), and 
nausea (16 vs. 32 vs. 31 vs. 20 vs. 
20 vs. 10%)
>90% 1 patient in groups 
C and D (DCV/
SOF) and one 
patient in groups E 
and F (DCV/SOF/
RBV) discontinued 
the treatment
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Treatment/study group/
year
Population Adverse event (AE) profile Overall 
SVR
12
 rate
Treatment status
DCV 20 mg/PegIFN/RBV 
(n = 159) vs. DCV 60 mg/ 
PegIFN/RBV (n = 158) 
vs. placebo/PegIFN/RBV 
(n = 78) (2015) [29]
395 treatment-
naïve patients with 
HCV genotype 
1 or 4
A higher percentage of patients 
in placebo/PegIFN/RBV group 
had treatment failure compared 
to patients in DCV 20 mg or 
60 mg groups (62.5 vs. 40.4 vs. 
40.8%)
Among the most common AEs 
in DCV 20, 60 mg, and placebo 
group, there were fatigue (55.3 
vs. 54.4 vs. 59%), headache (42.8 
vs. 43 vs. 46.2%), pruritus (35.2 
vs. 39.9 vs. 33.3%), insomnia (30.8 
vs. 33.5 vs. 38.5%), and rash (34 
vs. 25.3 vs. 32.1%)
>90% 7 patients in DCV 
20 mg group, 
seven patients in 
DCV 60 mg group, 
and eight patients 
in placebo group
DCV/SOF/RBV for 12 
(n = 24) or 16 weeks 
(n = 26) (2016) [30]
50 treatment-
naïve (n = 13) 
or treatment-
experienced 
(n = 37) genotype 
3 patients 
with advanced 
fibrosis (n = 14) 
or compensated 
cirrhosis (n = 36)
The most common AEs occurring 
in at least 10% of patients in 
DCV/SOF/RBV for 12 weeks or 
16 weeks groups were insomnia 
(33.3 vs. 26.9%), fatigue (25 
vs. 26.9%), headache (29.2 vs. 
19.2%), irritability (20.8 vs. 7.7%), 
asthenia (8.3 vs. 19.2%), and 
diarrhea (4.2 vs.15.4%)
Overall 
90%
No AEs leading 
to treatment 
discontinuation
SMV/PegIFN/RBV 
(n = 260) vs. placebo/
PegIFN/RBV (n = 133) 
(2014) [31]
393 genotype 1 
HCV patients
Frequently associated AEs in 
SMV/PegIFN/RBV and placebo 
groups were fatigue (31.9 vs. 
42.1%), headache (31.9 vs. 36.1%), 
and influenza-like symptoms 
(29.6 vs. 20.3%)
2 patients in SMV group had 
grades 2/3 photosensitivity 
events
6.2% of patients SMV/
PegIFN/RBV had grades 
3/4 hyperbilirubinemia (the 
frequency in placebo group was 
3.1%)
80–83% 0.4% of patients in 
SMV/PegIFN/RBV
SMV + SOF ± RBV for 
12 weeks vs. 24 weeks 
(2014) [32]
167 genotype 
1 chronic HCV 
patients
Most common AEs in pooled 
groups of patients treated with 
different simeprevir/sofosbuvir 
combinations included headache 
(20%), nausea (16%), and 
fatigue (31%). Grade 4 AEs were 
observed in one patient (2%) in 
each of groups 1 and 3, in three 
patients (10%) of group 2, while 
grades 3–4 AEs were scrutinized 
in less than 5% of the patients 
except the elevated level of blood 
amylase
92 and 94% 
for cohorts 
1 and 2
4 patients (2%) had 
withdrawn from 
all study treatment 
due to AEs and 
three patients 
discontinued 
before week 12
Safety, Tolerability, and Associated Side Effects of Direct-Acting Antivirals
http://dx.doi.org/10.5772/intechopen.76225
169
Treatment/study group/
year
Population Adverse event (AE) profile Overall 
SVR
12
 rate
Treatment status
DCV 60 mg QD + ASV 
200 mg BID × 24 weeks 
(group A1; n = 18) vs. 
DCV 60 mg QD + ASV 
200 mg QD ×2 4 weeks 
(group A2; n = 20) vs. DCV 
60 mg QD + ASV 200 mg 
BID + PegIFNα/RBV × 
24 weeks (groupB1; n = 20) 
vs. DCV 60 mg QD + ASV 
200 mg QD + PegIFNα/
RBV × 24 weeks (group 
B2; n = 21) vs. DCV 
60 mg QD + ASV 200 mg 
BID + RBV × 24 weeks 
(group B3; n = 22) (2014) 
[33]
101 genotype 
1a and 1b HCV 
patients
Frequently associated AEs in all 
groups were headache (44 vs. 40 
vs. 60 vs. 48 vs. 46%), diarrhea 
(28 vs. 30 vs. 45 vs. 33 vs. 23%), 
fatigue 28 vs. 10 vs. 40 vs. 24 vs. 
32%), asthenia (17 vs. 20 vs. 30 vs. 
57 vs. 32%), myalgia (22 vs. 5 vs. 
10 vs. 38 vs. 9%), and insomnia 
(17 vs. 15 vs. 45 vs. 14 vs. 41%)
Group 
A1 (78%), 
group A2 
(65%), 
group B1 
(95%), and 
group B2 
(95%)
1 patient in B3 
group
DCV/ASV/PegIFN/RBV for 
24 weeks (2015) [34]
398 genotype 1 
or 4 chronic HCV 
patients
Frequently associated AEs 
were fatigue (41.5%), headache 
(31.2%), pruritus (26.1%), 
asthenia (24.1%), influenza-like 
illness (22.4%), and insomnia 
(22.4%)
Genotype 1 
(93%) and 
genotype 4 
(98%)
18 patients
PrOD with RBV (group 
A) (n = 437) vs. matching 
placebos (group B) 
(n = 158) (2014) [35]
595 previously 
untreated 
genotype 1 HCV 
patients
Common AEs in groups A and 
B (P < 0.05 for each comparison) 
were fatigue (34.7 vs. 28.5%), 
headache (33.0 vs. 26.6%), nausea 
(23.7 vs. 13.3%), pruritus (16.9 vs. 
3.8%), insomnia (14.0 vs. 7.6%), 
diarrhea (13.7 vs. 7.0%), and 
asthenia (12.1 vs. 3.8%)
Genotype 
1a (95%) 
and 
genotype 
1b (98%)
3 Patients in group 
A and 1 patient in 
group B
PrOD with RBV (n = 297) 
vs. placebo (n = 97) during 
the 12-week double-blind 
period/2014 [36]
394 Previously 
treated with 
PegIFN/RBV who 
had a relapse, a 
partial response, 
or a null response 
in patients with 
HCV genotype 1 
infection without 
cirrhosis
Common AEs in active and 
placebo groups were headache 
(36.4 vs. 35.1%; P = 0.90), fatigue 
(33.3 vs. 22.7%; P = 0.06), and 
nausea (20.2 vs. 17.5%). More 
patients in the active-regimen 
group had anemia (P = 0.01), and 
vomiting (P = 0.006); while AEs 
with a higher frequency in the 
placebo group were constipation 
(P = 0.02), erythema (P = 0.05), 
neck pain (P = 0.05), and 
neutropenia (P = 0.01).
96.3% 
overall
3 patients in the 
active regimen 
group
86 patients were 
treatment-naïve (44 
received PrOD and 42 
received PrOD/RBV) and 
49 treatment-experienced 
patients received the RBV-
containing therapy/2015 
[37]
135 genotype 4 
chronic HCV
Most common AEs were 
headache (29% of treatment-
experienced patients vs. 33% 
of 42 treatment-naïve patients), 
asthenia (24 vs. 33%), fatigue (7 
vs. 18%), insomnia (5 vs. 16%), 
and nausea (9 vs. 17%)
100% RBV-
containing 
regimen 
and 90.9% 
RBV-free 
regimen
No AEs leading 
to treatment 
discontinuation
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and nervous system disorders were mostly found in sofosbuvir®/RBV-treated patients as com-
pared to the placebo group [24, 25]. Efficacy and safety of daclatasvir®/sofosbuvir® with or 
without RBV was assessed in more than 600 patients with advanced HCV disease. Population 
was mostly cirrhotic (72%, of whom 18% were decompensated), HCV treatment-experienced 
(82%), and infected with genotypes 1 (69%), 3 (12%), or 4 (19%). Most of them were treated 
for 24 weeks and 14% received RBV. Twelve weeks of SVR was 92% overall, 90% in cirrhotic 
patients, and 95% in non-cirrhotic patients. Twelve weeks of SVR (SVR12) remained constant 
among all major six genotypes and antiretroviral regimens. Among 617 patients with safety 
data, seven patients discontinued due to adverse events and ten died. About three out of seven 
reported discontinuation as AEs were consequently found fatal (decompensated cirrhosis/multi-
organ failure, respiratory disorder, hepatic carcinoma) and for the remaining four were nonfatal 
(treatment-associated lymphopenia, renal insufficiency) [26]. Daclatasvir®/sofosbuvir® with or 
without RBV achieved high SVR12 and was well tolerated in this large real-world cohort of 
HIV-/HCV-coinfected patients with advanced liver disease. Conclusively, it is found that dacla-
tasvir®/sofosbuvir® with or without RBV is well tolerated in real-world HIV-/HCV-coinfected 
cohort with advanced hepatic disease, and treatment is more suitable in this perspective [26].
Safety profile of sofosbuvir®/ledipasvir® combination with or without RBV was evaluated in 
pivotal study trials including ION-1, ION-2, and ION-3. In these clinical trials, 2000 HCV-infected 
Treatment/study group/
year
Population Adverse event (AE) profile Overall 
SVR
12
 rate
Treatment status
PrOD with RBV (group 
1) vs. PrOD (group 2)/ 
2014 [38]
179 patients with 
HCV genotype 
1b infection, 
without cirrhosis, 
previously treated 
with PegIFN/RBV
The most frequently reported 
AEs in groups 1 and 2 were 
fatigue (31.9 vs. 15.8%), headache 
(24.2 vs. 23.2%), and nausea 
(20.9 vs. 6.3%). Patients treated 
with RBV had more commonly 
insomnia, anemia, rash, and 
increased blood bilirubin levels
Group 1 
97% and 
group 2 
100%
1 patient in group 
1 and 1 patient in 
group 2
GZP/EBR (immediate 
treatment group) (n = 
111) vs. placebo (deferred 
treatment group) (n = 
113)/2015 [39]
224 patients with 
HCV genotype 
1 infection and 
chronic kidney 
disease
Common AEs occurred in 
patients in immediate treatment 
and deferred treatment groups 
were headache (17.1 vs. 16.8%), 
nausea (15.3 vs. 15.9%), fatigue 
(9.9 vs. 15%), insomnia (6.3 vs. 
10.6%), dizziness (5.4 vs. 15.9%), 
and diarrhea (5.4 vs. 13.3%)
99% 5 patients in 
deferred treatment 
group
GZP/EBR/ 2015 [40] 218 treatment-
naïve patients 
with chronic HCV 
genotype 1, 4, or 
6 infection and 
HIV co-infection, 
with or without 
cirrhosis
The most frequent AEs were 
fatigue (13%), headache (12%), 
and nausea (9%).
96% There were no 
AEs leading 
to treatment 
discontinuation
Table 2. Clinical efficacy and tolerability of direct acting antivirals (DAAs).
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patients (cirrhotic and non-cirrhotic) with genotype 1 were treated with ledipasvir®/sofos-
buvir® or ledipasvir®/sofosbuvir® plus RBV. Ledipasvir® was found to be associated with 
the occurrence of headache, insomnia, nausea, and asthenia. In data obtained from ION-2 
and ION-3 trials, AEs such as cough, rash, grade 1 or 2 hyperbilirubinemia, arthralgia, ane-
mia, irritability, and dyspnea were found frequently among patients treated with RBV [27, 28]. 
Furthermore, outcomes of treatment combinations like daclatasvir®/pegIFN/RBV vs. placebo, 
daclatasvir®/sofosbuvir®, and with or without RBV, were evaluated in ALLY-3+, AI444040, and 
AI444010 clinical studies, respectively, in more than 650 patients having genotype of 1, 2, 3, 
or 4. Like other DAAs symptoms like asthenia, headache, and nausea were more frequently 
observed [29–31]. AI444040 study illustrated discontinuation of therapy in two patients, one 
having stroke with history of hyperlipidemia, smoking, and myocardial infarction and the 
other having fibromyalgia exacerbation with history of fibromyalgia [29]. According to another 
efficacy study, in placebo group a large number of patients had grade 3–4 AEs when com-
pared with patients who received daclatasvir® 20 or 60 mg (23.1 vs. 20.1 vs. 14.6%). In 3.8% of 
patients receiving 60 mg daclatasvir®, an increased alanine aminotransferase (ALT) level was 
observed vs. 1.3% of patients in placebo group, while patients receiving 20 mg daclatasvir® did 
not experience this side effect. However, both groups of drug dosage experienced the symp-
toms of influenza-like syndrome, nausea, and dry skin [30]. In ALLY-3+ phase III study trial, 
no AEs were observed in patients receiving daclatasvir®/sofosbuvir®, with RBV which led to 
discontinuation of therapy. The most common treatment-associated general side effects includ-
ing irritability, insomnia, asthenia, fatigue, dyspnea, and diarrhea were observed in 10% of the 
patients. The high level of safety and clinical efficacy was demonstrated in patients having chal-
lenging viral 3a genotype who were administered with this combination for 12 or 16 weeks [31].
2.1.2. Efficacy and safety analysis of simeprevir® in different combinations
Simeprevir® in combination with PegIFNα and RBV was assessed in more than 1000 patients 
using QUEST-1, QUEST-2, and PROMISE clinical trials. AEs associated with simeprevir® 
included rash, increased bilirubin level, pruritus, and photosensitivity events as compared 
to the placebo group. No differences were found in PROMISE trial between simeprevir®/
PegIFN/RBV and placebo groups for frequency of grades ¾ AEs [32]. Simeprevir® in combi-
nation with sofosbuvir® was approved by the FDA in 2014 for chronic patients of genotype 
1. In COSMOS randomized study, patients were grouped in ratio of 2:1:2:1 who received 
simeprevir® (150 mg) and sofosbuvir® (400 mg) for 24 weeks with (group 1) or without 
(group 2) RBV and for 12 weeks with (group 3) or without (group 4) RBV, in two different 
cohorts: previously nonresponders having METAVIR1 scores of F0–F2 and treatment-naïve 
patients and previously nonresponders with F3–F4 scores of METAVIR [33]. In cohorts 1 and 
2, 92 and 94% of patients achieved SVR12, respectively. Most common AEs in pooled groups 
of patients treated with different simeprevir®/sofosbuvir® combinations included headache 
(20%), nausea (16%), and fatigue (31%). Grade 4 AEs were observed in one patient (2%) in 
each of groups 1 and 3 and in three patients (10%) of group 2, while grades 3–4 AEs were 
scrutinized in less than 5% of the patients except the elevated level of blood amylase. Serious 
1Scoring system used to assess the extent of inflammation and fibrosis via histopathological evaluation in liver biopsy 
of HCV patients.
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AEs were observed in four patients (2%); four patients (2%) had withdrawn from all study 
treatment due to AEs, and three patients discontinued before week 12 [33].
2.1.3. Tolerability analysis of asunaprevir® combinations
In a randomized phase 2a open-label study, safety and tolerability of asunaprevir®/dacla-
tasvir® combination therapy was assessed in 100 patients of genotype 1a and 1b. Patients 
received five different regimens including daclatasvir® and asunaprevir® alone, at differ-
ent dosages, or plus PegIFN/RBV. Efficacy data depicted that asthenia, headache, and diar-
rhea were more common and that serious hematological side effects were found in patients 
who received PegIFN and/or RBV. Correspondingly, flu-like illness, alopecia, and rash were 
observed in patients treated with PegIFN and/or RBV compared to those who treated with 
daclatasvir® and asunaprevir® [34]. During trials six severe AEs were analyzed: one patient 
got panic attack, one case of forearm fracture, one case of prostate cancer found in patients 
who received asunaprevir®/daclatasvir® combination, two over dosage cases, and one case 
of squamous cell carcinoma in patients treated with daclatasvir®/asunaprevir®/ PegIFN/
RBV [33]. In phase 3 study of HALLMARKQUAD trial, patients with genotype 1 (n = 354) 
or genotype 4 (n = 44) (partial or nonresponders to PegIFN/ RBV) were treated daily with 
daclatasvir®/asunaprevir® combination and weekly with PegIFN and/or RBV. In serious AEs 
(5.5% of patients), grade ¾ clinical manifestations included lymphopenia, thrombocytopenia, 
neutropenia, anemia, and elevated level of ALT/aspartate transaminase (AST) were found in 
the treated patients. Fatigue, pruritus, influenza-like symptoms, rash, asthenia, and insomnia 
were common AEs observed during study. Negligible difference was found in ALT and AST 
elevation among patients with or without cirrhosis [35]. Drug combination was well tolerated, 
and no additional safety concerns were identified in comparison to pegIFN/RBV regimens.
2.1.4. Efficacy study of ombitasvir®/paritaprevir®/ritonavir®
Safety analysis of ombitasvir®/paritaprevir®/ritonavir® in combination with dasabuvir® was 
analyzed among 1025 patients during clinical trials of SAPPHIRE-I and SAPPHIRE-II. Clinical 
efficacy data depicted that headache and fatigue were the most frequent AEs. In comparison 
to placebo group, patients treated with ombitasvir®/paritaprevir®/ritonavir®, dasabuvir®, 
and RBV were found to exhibit asthenia, diarrhea, pruritus, nausea, and insomnia as the most 
common AEs. On the other hand, placebo group patients were confronted to have erythema, 
neck pain, and constipation. Ventricular extra systoles, sinus tachycardia, acute respiratory 
failure, and acute transient stroke were reported as severe AEs in study treatment [36, 37]. In 
PEARL-I and PEARL-II trials, safety results in HCV-infected patients of genotypes 1 and 4 
who were treated with combination of ombitasvir®/paritaprevir®/ritonavir®, with or with-
out dasabuvir®, and RBV® illustrated that insomnia, nausea, asthenia, and headache were 
the most common AEs [38, 39].
2.1.5. Safety analysis of grazoprevir®/elbasvir® combination
According to C-SURFER safety study data, in which 244 patients of viral genotype 1 along 
with chronic kidney disease (CKD) were included, grazoprevir®/elbasvir® combination was 
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associated with AEs like nausea, headache, and fatigue. In two patients cardiac arrest and 
myocardial infarction were observed, while in placebo group, three patients were reported 
with serious cardiac events. Though the severities and frequencies of liver-associated events 
were comparable between groups, elevation in ALT and AST levels were more frequent in 
placebo group. In grazoprevir®/elbasvir®-treated group of patients, a low hemoglobin level 
(24.3 vs. 16.8%) was recorded [40]. In single-arm C-EDGE COINFECTION phase 3 study, 
safety of grazoprevir®/elbasvir® was assessed in patients (n = 218) of genotype 1, 4, or 6 coin-
fected with HIV. Related to the previous study, the most frequent AEs were nausea, fatigue, 
and headache [41].
2.2. Post-marketing safety reports of DAAs
Post-marketing survey studies scrutinizing the efficacy profile of clinically approved DAAs are 
very limited. Probing the altered drug metabolism among patients receiving HCV treatment 
with other clinical manifestations, drug-drug interactions and concurrently administered 
medications remain at the front position for optimizing DAA regimen. A study regarding 
DAA/non-DAA drug interaction recommended that simeprevir®/pegIFN/RBV may increase 
the risk of interstitial pneumonitis due to IFN as evinced by earlier onset of condition while 
comparing to conventional pegIFN/RBV treatment [42]. Another study regarding DAA/non-
DAA drug interaction in a patient with recurrent HCV and cirrhosis first reported the case 
of seizures, possibly participated by simeprevir®/sofosbuvir®/RBV therapy [43]. Whereas 
risk of interstitial pneumonitis and seizures is still being evaluated, extensive cases of cardiac 
events in patients who received simeprevir®/sofosbuvir® and amiodarone®, an anti-arrhyth-
mic medication having long half-life, led to extra care on the account of prescribing providers 
and an appendix on labels of antiviral drugs. Most cases of liver decompensation or hepatic 
failure from the post-approval use of simeprevir®/pegIFN/RBV or with sofosbuvir® were 
recorded by patients of advanced cirrhosis who were formerly at high risk for deteriorating 
liver function. Due to limited data available, simeprevir® is contraindicated in patients with 
severe cirrhosis or decompensated liver disease [44, 45]. Due to potent toxicity, the three-
dimensional (3D) therapies are contraindicated in patients suffered from severe liver impair-
ment [46, 47]. A total of 26 cases globally were significantly found to be related to 3D therapy 
administration with liver disorder occurring within 1–4 weeks of starting treatment [48, 49]. 
Moreover, it was revealed from real-world data that high incidence of primarily hypersensi-
tivity reactions and immune system disorders may often lead to liver failure [49].
Post-marketing data obtained from HCV-/HIV-coinfected patients led to commendations for 
patients to stay on suppressive antiretroviral regimen while on 3D therapy due to the pres-
ence of ritonavir® (HIV-1 protease inhibitor) that can select for HIV-1 protease inhibitor resis-
tance-associated substitutions [46–49]. Very low treatment discontinuation and AE rates were 
found in phase II–III study regarding sofosbuvir®-containing regimen as compared to IFN-
based therapy while analyzing real-world results [50, 51]. Data depicted that two patients had 
to stop anti-HCV therapy earlier due to variceal bleeding and nonmedical reasons. However, 
therapy was well tolerated for majority of the patients (97%) [52]. Overall, Child-Pugh2 and 
2Score used to analyze prognosis of chronic hepatic disease, specifically cirrhosis.
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Model for End-Stage Liver Disease3 (MELD) classifications improved for majority of HCV-
infected patients, therefore lessening the need for transplantation of the liver. Post-marketing 
data obtained from CHC patients with renal disease depicted that same treatment was safe 
and tolerable regardless of baseline kidney function, yet patients who received sofosbuvir®-
containing regimen seemed to have higher incidence of anemia [50].
3. Anti-HCV drug combinations tolerability in distinctive 
population
Significant AE profile of IFN-based therapy confines the applicability of these regimens for 
treating recurrent hepatitis C infection in difficult-to-treat population. Intensive research 
struggles are being done to assess DAAs in different populations of CHC patients for whom 
therapeutic options are limited.
3.1. Elderly CHC patients
Recently, evidence-based retrospective cohort studies have been reported regarding safety 
and tolerability analysis of DAAs in elderly CHC patients. Patients (n = 244) were categorized 
into two groups: individuals aged under 65 years (n = 156) and patients equal to or elder 
than 65 years (n = 84). Treatment recommendations during the late 2012 and early 2013 were 
protease inhibitors in combination with pegIFN and RBV. During years of 2014 and 2015, the 
rest of the therapies were given to patients as approved in succession by the FDA. Different 
treatment combinations used were sofosbuvir®/pegIFN/RBV, sofosbuvir®/ledipasvir®/RBV, 
ombitasvir®/paritaprevir® /ritonavir®/dasabuvir® ± RBV, and simeprevir®/sofosbuvir®. 
Just three patients received telaprevir®/pegIFN/RBV, and one patient each was treated with 
boceprevir®/pegIFN/RBV, sofosbuvir®/ledipasvir®/RBV, and simeprevir®/sofosbuvir®/RBV 
combinations in cohort study [53]. With all regimen combinations, the overall end-of-treat-
ment (EOT) response rate, defined as undetectable HCV RNA transcript after the completion 
of treatment, was 98.2% (n = 233) and SVR12 was 94% (n = 191). Statistically, no significant dif-
ference was found with EOT (98.8 vs. 98%) and SVR12 (93.1 vs. 94.1%) between patients aged 
65 years or older and those younger than 65 years. SVR12 for DAAs/pegIFN/RBV was 98% 
higher than that (91.4%) obtained from IFN-free DAA regimen but was statistically insignifi-
cant. Analogous response rate was seen in patients aged 65 or older with 100% of the patients 
on IFN-based therapy attaining an SVR compared with only 91.07% SVR with IFN-free ther-
apy [53]. No serious AEs were reported except two patients suffered from severe anemia. 
Common AEs observed in elder patients were fatigue (32.5%), anemia (19.6%), and leuko-
penia (11.7%) followed by thrombocytopenia (10%), skin rash (8.3%), and headache (7.9%). 
Leucopenia, thrombocytopenia, and anemia were observed in almost half of the patients 
treated with IFN/RBV. By reducing RBV dose, all patients achieved SVR12. Treatment dis-
continuation of RBV dose reduction did not attain statistical significance among both groups. 
Conclusively, on the basis of cohort studies, we can say that age is not a major factor to have an 
3Classification used to categorize liver dysfunction in preparation for liver transplantation.
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impact on SVR during treatment. Older patients did not attain higher frequency of AEs while 
comparing with younger patient group. Some other clinical manifestations like fibrosis, cir-
rhosis, ALT/AST, hemoglobin, and platelet levels may disturb the SVR in the elderly [53, 54].
3.2. Transplant recipients with chronic hepatitis C infection
HCV-related hepatic disease generally arises in patients following liver transplantation. 
Nearly half of the patients who have the need of liver transplant are also infected with hepa-
titis C infection. Viremia before transplantation is a strong predictor of virus recurrence post-
transplantation. IFN-free DAA therapy has improved the long-term, posttransplantation 
sequel. Preeminently, DAA therapy leads to drug-drug interaction with different immuno-
suppressants, mainly with cyclosporine and tacrolimus. As both are substrates of CYP3A and 
P-glycoprotein (P-gp), treatment should be restricted to agents that are neither inducers nor 
inhibitors of these molecules. Currently, in a recent trial, combination of antiviral drugs (ombi-
tasvir®/paritaprevir®/ritonavir® (25/150/150 mg q.d4)/dasabuvir® (250 mg b.d5)/variable RBV 
dose) was given for 24 weeks to transplant recipients having recurrent viral genotype 1 infec-
tion and without advanced stages of fibrosis [55]. Clinically, manageable AEs such as head-
ache, cough, and fatigue were found to be associated with therapy. Momentarily, elevated 
levels of ALT and bilirubin were noticed in two patients, and nine patients were reported to 
have a reduced level of hemoglobin with one patient requiring erythropoietin. No significant 
treatment-associated abnormalities were observed in transplant recipients while comparing 
with those who had not undergone transplantation. Only one patient quitted treatment after 
18 weeks due to memory impairment, anxiety, and rash but still cleared out the virus. Major 
limitation of this therapy was the need to improve tacrolimus and cyclosporine dosage [55].
In another trials, efficacy and safety of IFN-free sofosbuvir®/RBV therapy to treat CHC infec-
tion in kidney transplant recipients (n = 10) were evaluated. The effect of sofosbuvir®/RBV 
therapy upon calcineurin inhibitor (CNI) drug levels was also assessed. SVR12 was seemed to 
be maintained in all patients (100%) [56, 57]. Acute rejection graft loss was not detected during 
antiviral therapy. Among ten patients, seven did not exhibit significant AEs. Only one patient 
had symptoms of fatigue, muscle cramps, headache, and anorexia during therapy. Acute gas-
troenteritis was observed in one patient who recovered after 5 days. Another patient was found 
to have hyperuricemia with gout, but its association with sofosbuvir/RBV treatment was not 
recognized. All patients completed the course of treatment, and none of the patients discon-
tinued their antiviral treatment. Significant reduction in CNI drug exposure was found during 
anti-HCV treatment, but none of the patients required having dose modification of CNIs [56].
3.3. HCV-/HIV-coinfected patients
HCV-/HIV-coinfected patients are at high risk for progression of liver cirrhosis and hepatic 
decompensation. One study assessed IFN-free ombitasvir®/paritaprevir®/ritonavir® (25/150/ 
100 mg q.d.) and dasabuvir® (250 mg b.d.) regimen in HCV-/HIV-coinfected patients for 
12 or 24 weeks [58]. This therapy was found well tolerated in study population including 
4One tablet per day orally (Latin: quaque die).
5Twice a day (Latin: bis in die).
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treatment-experienced and treatment-naïve patients and cirrhotic and non-cirrhotic patients. 
Mild-to-moderate AEs were experienced by majority of the patients (89%); however, one patient 
was found to have severe AEs, but none of the patients discontinued their therapy due to AEs. 
Along with infrequent laboratory abnormalities, no erythropoietin or transfusion was required 
by any patient. Ledipasvir® (90 mg q.d.) and sofosbuvir® (400 mg q.d.) treatment to HCV-/HIV-
coinfected patients for 12 weeks stated mild-to-moderate AEs (77%) including fatigue, head-
ache, and diarrhea [59]. Less than 1% of the patients were reported for laboratory abnormalities 
including increased levels of creatinine kinase (non-study-related), lipase, and serum glucose 
(in those patients who had history of diabetes or abnormal baseline glycosylated hemoglobin 
levels). However, no patient was reported to discontinue therapy due to AEs. Consequently, 
this therapy displayed less potential for clinically significant drug-drug interactions with coad-
ministration of antiretrovirals except with the drug, tenofovir disoproxil fumarate [59].
4. Conclusion
The last few years evidently made the progress in development of successful HCV therapeutic 
regimens with higher clinical efficacy and inconsiderable side effects except some with severe 
AEs, but negligible treatment discontinuation rate was reported. Likewise, therapy duration 
with DAAs is markedly reduced from 6 to 12 months (pegIFN/RBV) to 3–6 months. So, develop-
ment of DAAs has remarkably changed the disease management. Despite various advantages 
of DAA therapy, their safety profile is albeit not absolutely known. Indeed, interpreting the 
constraints of premarketing studies like population size and short duration trials, only during 
the post-approval level, it is probable to ascertain and apprehend the safety matters linked with 
the utilization of DAAs in real conditions. As a result, pharmacovigilance activities portray the 
main gadget to promote patient care and safety in comparison to the use of any medication.
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